Biocon Ltd. announced the launch of Everolimus tablets, a generic version of Afinitor®, in the US. Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet being a `day-1' generic launch. Everolimus (Afinitor®) is a prescription medication that is used to treat certain types of cancers and tumours. The commercial launch of Everolimus follows an US FDA approval in February 2021. The Everolimus launch is further assertion of Biocon's strategy to focus on vertically integrated, complex Finished Dosage Formulations (FDF) in niche therapeutic areas, using in-house Active Pharmaceutical Ingredient (API) capabilities.